Autopsy report · NCT01528501

Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008)

“medical/ethical reasons”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 8 months after it had already started.
• 28 participants planned (an estimate, not an actual count).
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Technical University of Munich

Sponsor type

University, hospital or other

Conditions

Metastatic Gastric Cancer

Interventions

Panobinostat (LBH589)

Participants

28 (planned, not actual)

Sites

2

Countries

Germany

Trials that died the same way

• KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors
  “Business reasons” (64% match in meaning)
• Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
  “Financial/Business Reasons” (61% match in meaning)
• Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation
  “Organizational reasons” (60% match in meaning)
• First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
  “Business/Commercial Reasons” (59% match in meaning)
• Intermittent Oral-esophageal Tube in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma
  “ethical issues” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.